Increased Infiltration of Tumor Associated Macrophages is Associated With Poor Prognosis of Bladder Carcinoma In Situ After Intravesical Bacillus Calmette-Guerin Instillation

Journal of Urology

Volumn 181, Issue 4, 2009, Pages 1894-1900

  Takayama, Hitoshi ^a   Nishimura, Kazuo ^a   Tsujimura, Akira ^a   Nakai, Yasutomo ^a   Nakayama, Masashi ^a   Aozasa, Katsuyuki ^a   Okuyama, Akihiko ^a   Nonomura, Norio ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

BCG vaccine; carcinoma in situ; macrophages; prognosis; urinary bladder

Indexed keywords

BCG VACCINE; MONOCLONAL ANTIBODY; PARAFFIN;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER CELL; CANCER RECURRENCE; CARCINOMA IN SITU; CELL INFILTRATION; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LAMINA PROPRIA; MACROPHAGE; MALE; PRIORITY JOURNAL; PROGNOSIS; STAINING; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; AGED; AGED, 80 AND OVER; BCG VACCINE; CARCINOMA IN SITU; CELL MOVEMENT; FEMALE; HUMANS; MACROPHAGES; MALE; MIDDLE AGED; PROGNOSIS; URINARY BLADDER NEOPLASMS;

EID: 61949486981     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2008.11.090     Document Type: Article

References (20)

1. Melicow M.M. Histological study of vesical urothelium intervening between gross neoplasms in total cystectomy. J Urol 68 (1952) 261
2. Lamm D.L. Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am 19 (1992) 573
3. Lamm D.L., Blumenstein B.A., Crawford E.D., Montie J.E., Scardino P., Grossman H.B., et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional cell carcinoma of the bladder. N Engl J Med 325 (1991) 1205
4. Brosman S.A. The use of bacillus Calmette-Guerin in the therapy of bladder carcinoma in situ. J Urol 137 (1985) 36
5. Kim J.C., and Steinberg G.D. The limits of bacillus Calmette-Guerin for carcinoma in situ of the bladder. J Urol 165 (2001) 745
6. Witjes J.A. Bladder carcinoma in situ in 2003: state of the art. Eur Urol 45 (2004) 142
7. de Reijke T.M., de Boer E.C., Kurth K.H., and Schamhartm D.H. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value. J Urol 155 (1996) 477
8. Thalmann G.N., Dewald B., Baggliolini M., and Studer U.E. Interleukin-8 expression in the urine after bacillus Calmette-Guerin therapy: a potential prognostic factor of tumor recurrence and progression. J Urol 158 (1997) 1340
9. Jackson A.M., Ivshina A.V., Senko O., Kuznetsova A., O'Donnell M.A., Clinton S., et al. Prognosis of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer by immunological urinary measurements: statistically weighted syndrome analysis. J Urol 159 (1998) 1054
10. Saint F., Patard J.J., Maille P., Soyeus P., Hoznek A., Salomon L., et al. T helper 1/2 lymphocyte urinary cytokine profiles in responding and nonresponding patients after 1 and 2 courses of bacillus Calmette-Guerin for superficial bladder cancer. J Urol 166 (2001) 2142
11. Mantovani A., Bottazi B., Colotta F., Sozzani S., and Ruco L. The origin and function of tumor-associated macrophages. Immunol Today 13 (1992) 265
12. Balkwill F., and Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 357 (2001) 539
13. Sica A., Schioppa T., Mantovani A., and Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 42 (2006) 717
14. Wahl L.M., and Kleinman H.K. Tumor-associated macrophage as target for cancer therapy. J Natl Cancer Inst 90 (1998) 1583
15. Leek R.D., Lewis C.E., Whitehouse R., Greenall M., Clarke J., and Harris A.L. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 6 (1996) 4625
16. Welsh T.J., Green R.H., Richardson D., Waller D.A., O'Byne K.J., and Bradding P. Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol 35 (2005) 8959
17. Hanada T., Nakagawa M., Emoto A., Nomura T., and Nomura Y. Prognostic value of tumor-associated macrophage count in human bladder cancer. Int J Urol 7 (2000) 263
18. Koga F., Kageyama Y., Kawakami S., Fujii Y., Hyochi N., Ando N., et al. Prognostic significance of endothelial Per-ARNT-Sim domain protein 1/hypoxia-inducible factor-2α expression in a subset of tumor associated macrophages in invasive bladder cancer. J Urol 171 (2004) 1080
19. O'Donnell M.A., Luo Y., Chen X., Szilvasi A., Hunter S.E., and Clinton S.K. Role of IL-12 in the induction and potentiation of IFN-gamma in response to bacille Calmette-Guérin. J Immunol 163 (1999) 4246
20. Ratliff T.L., Palmer J.O., McGarr J.A., and Brown E.J. Intravesical bacille Calmette-Guérin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of bacille Calmette-Guérin. Cancer Res 47 (1987) 1762